Semler Scientific, Inc.SMLREarnings & Financial Report
Semler Scientific, Inc. develops, manufactures and distributes non-invasive medical diagnostic devices for chronic disease screening. Its flagship QuantaFlo system delivers fast, accurate peripheral arterial disease testing, serving hospitals, clinics, primary care practices and other healthcare providers primarily in the United States.
Revenue
$14.5M
Gross Profit
$13.2M
Operating Profit
$5.3M
Net Profit
$11.0K
Gross Margin
91.3%
Operating Margin
37.0%
Net Margin
0.1%
YoY Growth
-22.3%
EPS
$0.00
Semler Scientific, Inc. Q2 FY2024 Financial Summary
Semler Scientific, Inc. reported revenue of $14.5M (down 22.3% YoY) for Q2 FY2024, with a net profit of $11.0K (down 99.8% YoY) (0.1% margin). Cost of goods sold was $1.3M, operating expenses totaled $7.9M.
Key Financial Metrics
| Total Revenue | $14.5M |
|---|---|
| Net Profit | $11.0K |
| Gross Margin | 91.3% |
| Operating Margin | 37.0% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
Semler Scientific, Inc. Q2 FY2024 revenue of $14.5M breaks down across 2 segments, led by Other at $7.5M (51.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $7.5M | 51.7% |
| Variable Fee Licenses | $7.0M | 48.3% |
Semler Scientific, Inc. Annual Revenue by Year
Semler Scientific, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $56.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $56.3M |
| 2023 | $68.2M |
| 2022 | $56.7M |
Semler Scientific, Inc. Quarterly Revenue & Net Profit History
Semler Scientific, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $7.5M | -44.6% | $16.9M | 225.6% |
| Q2 FY2025 | $8.2M | -43.2% | $66.9M | 814.6% |
| Q1 FY2025 | $8.8M | -44.4% | $-64.7M | -732.3% |
| Q4 FY2024 | $12.4M | -17.6% | $29.2M | 235.3% |
| Q3 FY2024 | $13.5M | -17.2% | $5.6M | 41.5% |
| Q2 FY2024 | $14.5M | -22.3% | $11.0K | 0.1% |
| Q1 FY2024 | $15.9M | -12.6% | $6.1M | 38.2% |
| Q4 FY2023 | $15.1M | +9.1% | $4.2M | 28.0% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.1M | $15.9M | $14.5M | $13.5M | $12.4M | $8.8M | $8.2M | $7.5M |
| YoY Growth | 9.1% | -12.6% | -22.3% | -17.2% | -17.6% | -44.4% | -43.2% | -44.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $78.1M | $83.9M | $84.8M | $92.2M | $239.8M | $293.4M | $522.6M | $596.7M |
| Liabilities | $6.3M | $6.0M | $6.4M | $6.8M | $9.1M | $131.8M | $139.2M | $136.9M |
| Equity | $71.8M | $77.9M | $78.4M | $85.4M | $230.8M | $161.7M | $383.4M | $459.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $4.4M | $5.6M | $4.9M | $6.4M | $7.4M | $-1.9M | $514000 | $-33.0M |